Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B-cell lymphoma, leg type.

Details

Ressource 1Download: 31110725_BIB_19B6596F010F.pdf (441.26 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_19B6596F010F
Type
Article: article from journal or magazin.
Publication sub-type
Case report (case report): feedback on an observation with a short commentary.
Collection
Publications
Institution
UNIL/CHUV
Title
Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B-cell lymphoma, leg type.
Journal
Clinical case reports
Author(s)
Al Dhafiri M., Sicre de Fontbrune F., Marinho E., Deschamps L., Di-Lucca J., Crickx B., Descamps V.
ISSN
2050-0904 (Print)
ISSN-L
2050-0904
Publication state
Published
Issued date
05/2019
Peer-reviewed
Oui
Volume
7
Number
5
Pages
964-967
Language
english
Notes
Publication types: Case Reports
Publication Status: epublish
Abstract
The primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) has a poor prognosis. R-CHOP with or without radiotherapy is the available recommendations for first-line treatment. Relapses/refractory cases are frequent with no standardized therapeutic guidelines. Lenalidomide seems to be an excellent therapeutic option as a second-line treatment of relapsed PCDLBCL-LT.
Keywords
chemotherapy, leg type, lenalidomide, primary cutaneous diffuse large B‐cell lymphoma
URN
urn:nbn:ch:serval-BIB_19B6596F010F5
OAI-PMH
oai:serval.unil.ch:BIB_19B6596F010F
DOI
10.1002/ccr3.2137
Pubmed
31110725
Web of science
000467564200023
Open Access
Yes
Create date
25/05/2019 11:40
Last modification date
15/01/2021 8:08
Usage data